Description

Biogen Acquisition Shock: Why The $5.6B Apellis Deal Could Be A Game-Changer!

Biogen entered 2026 with a stronger operating backdrop than it had a year earlier, reporting fourth-quarter and full-year 2025 results slightly above guidance, $3.3 billion in growth-product revenue, and a late-stage pipeline that management increasingly frames as the bridge to its next phase of expansion. Against that backdrop, Biogen’s March 31, 2026 agreement to acquire Apellis adds a new layer to that strategy. The proposed deal would bring in two commercialized complement medicines, EMPAVELI and SYFOVRE, for an upfront equity value of about $5.6 billion, plus contingent value rights tied to SYFOVRE sales milestones. Biogen has said the transaction would add immediate revenue, deepen its immunology and rare-disease portfolio, strengthen its nephrology capabilities, and become increasingly accretive to non-GAAP diluted EPS starting in 2027.